Tags
Blog

'Neuroscience Institute' posts

MS Roadshow coming April 26 to Skagit Valley

The MS Center at Swedish Neuroscience Institute will present the MS Roadshow April 26 in Mt. Vernon, Washington. The MS Roadshow is a free, half-day educational workshop about living well with multiple sclerosis (MS).

Knowledge really is power when it comes to managing your health. For people living with MS, learning as much as possible about the disease makes it easier to make informed decisions about your care.

Whether newly diagnosed or looking for more information to help improve your health, the MS Roadshow offers a look at leading-edge research and tips for living a full life. Topics and speakers include:

New medication for MS, Tecfidera (BG-12), Approved by FDA

On March 27, the U.S. Food and Drug Administration approved the newest treatment in the increasing number of disease modifying therapies (DMTs) available to treat multiple sclerosis. Tecfidera (BG-12) is an oral capsule to treat adults with relapsing forms of MS. Research participants at the MS Center at Swedish participated in clinical trials for Tecfidera.

 

The trials reported that people taking Tecfidera had fewer relapses and less frequent worsening of disability compared to people taking a placebo. There were also fewer and less-severe side effects with Tecfidera than other treatments.

 

The studies found that ...

Stride with Swedish April 14 for Multiple Sclerosis

Every hour, someone is diagnosed with multiple sclerosis (MS). And every day, people from around the Pacific Northwest and United States visit the MS Center at Swedish to learn how to live well with the disease.

Multiple sclerosis is a disease of the nervous system that affects the brain, eyes and spinal cord that takes a unique course in every patient. We’re with people on their journey, whether they are newly diagnosed or have been living with MS for decades. Patients and families share their lives with our treatment team and, in turn, we put our passion into helping them achieve their highest wellbeing.

Participating in Walk MS one way we show our commitment to caring for the MS community.

Dystonia Forum at Swedish Cherry Hill

We are excited to offer our annual Dystonia Forum coming up this Thursday at the Swedish Cherry Hill Campus. Click here to see the event flyer. It is not too late to register for lunch and a session that is sure to be informative and supportive. Hope you can join us!

Swedish Presents Research at 2013 AAN Annual Meeting

Neurologists and neuroscience professionals this week from around the world gathered at the American Academy of Neurology (AAN) 65th Annual Meeting in San Diego. The Multiple Sclerosis Center at Swedish Neuroscience Institute was pleased to co-author a few research trials presented at the meeting:

 

Teriflunomide and pregnancy

Dr. Lily Jung-Henson speaking at the AAN 65th Annual MeetingDr. Lily Jung-Henson, neurologist and Chief of Staff at Swedish Issaquah, spoke on behalf of a team of researchers about teriflunomide and a report on the safety of women who became pregnant on the medication. Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) recently approved in the United States to treat relapsing multiple sclerosis. Clinical trials for teriflunomide took place among the many research studies for new treatments Swedish Neuroscience Institute offers patients with multiple sclerosis. (Read the full abstract here.)

Subset of a trial looking at endurance effects of Dalfampridine (AMPYRA®)

Dr. Angeli Mayadev, physical medicine and rehabilitation specialist at the MS Center, participated in this study of a medication to improve walking speed in people with MS. Dalfampridine -ER 10 mg twice daily significantly improved 6-minute walking distance compared to placebo. Dalfampridine 5 mg twice daily did not improve distance compared to placebo. Researchers also found that ....

MS Research Update: Pulse therapy for breakthrough multiple sclerosis

A small pilot study from the University of Southern California suggests a pulse adrenocorticotropic hormone (ACTH) therapy could be effective in patients with breakthrough multiple sclerosis attacks while on beta-interferon. “Breakthrough” attacks that occur after starting a disease modifying therapy (DMT).

 

The study compared the safety and benefits of monthly pulse ACTH to monthly methylprednisone (MP) pulse in patients on beta-interferon. Over 15 months, researchers found that those treated with ACTH had fewer relapses and fewer psychiatric side effects. ACTH gel is currently used to treat MS relapses, but researchers note it may be able to alter the body’s immune responses beyond producing steroids.

 

As I discussed with the Medscape reporter, Megan Brooks, last week, the results of this study are ....

The benefits of DBS and neuromodulation: helping patients

After working in the field of neuromodulation for the past 25 years, I have seen many advances in the field; both in our understanding of the nervous system, and new technology designed to target specific neuronal pathways that will offer the best outcome for patients. It is an exciting field with new investigations that lead to ever expanding knowledge. However, what really keeps me interested in the field after all these years is the opportunity and privilege to be a part of our patients lives on a daily basis. The picture and comment shared below from a grateful patient who had DBS with us two years ago says it all…

"I look back on my experience at Swedish with a grateful heart... thankful for every day I've been given.."

Results 50-56 of 100